FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2035667023> ?p ?o ?g. }

• W2035667023 endingPage "352" @default.
• W2035667023 startingPage "350" @default.
• W2035667023 abstract "Arrhythmogenic right ventricular cardiomyopathy (ARVC), an inherited heart muscle disease, is associated with a high risk of arrhythmias and sudden cardiac death [1]. It is characterized primarily by fibrofatty replacement of the right ventricular myocardium, which is often accompanied by subsequent progression to the left ventricle [2], [3]. ARVC is genetically determined by autosomal dominant inheritance, although recessive subtypes have been observed [4]. Mutations in genes coding for desmosomal proteins, including desmoplakin, plakoglobin, plakophilin 2 (PKP 2), desmoglein 2, and desmocollin 2, have been identified in a significant number of patients [5]. The clinical presentation of ARVC varies widely; diagnosis is often complex and involves structural, histological, electrocardiographic, arrhythmic, and genetic tests for the disease [6]. Diagnosis is particularly difficult during the early phases of the disease when structural changes are not well-developed, leading to under-diagnosis. However, in this usually asymptomatic phase, some individuals may be at risk of sudden cardiac death. As such, it is important to increase the understanding of this complex condition through more patient-centered approaches, which may help with both diagnosis and management. Animal models have provided insight into the underlying mechanisms and pathophysiology of ARVC [4]. However, differences in functional and conduction properties between animal and human cardiomyocytes limit the general applicability of these results. The advent of induced pluripotent stem cell (iPSC) technology has greatly changed the landscape [7]. iPSCs are pluripotent stem cells derived from somatic cells through the induction of gene expression; these cells can then be reprogrammed to differentiate into other mature cell lines. In 2006, Yamanaka et al. pioneered this technology in mice followed by in human cells [7]. Since then, human iPSCs have been shown to be capable of differentiating into cardiomyocytes with cardiac-specific molecular, structural, and functional properties, indicating their great potential for the development of in vitro models of genetic cardiomyopathies [8]. Models patient-specific iPSCs have been used to study various inherited cardiac disorders. iPSC models were developed for the examination of long QT syndrome and have shed light on the mechanism of arrhythmogenicity in these cells (such as early-after depolarizations and triggered arrhythmias) and were used to evaluate the effectiveness of current and new agents to treat the disease phenotype [9]. For hypertrophic cardiomyopathy, iPSC models have increased the understanding of the molecular pathways of hypertrophy and arrhythmogenesis involved in abnormal calcium regulation and homeostasis within the cardiac sacromere [10]. Similar models have shed light on the pathogenesis and treatment of other cardiac disorders such as familial dilated cardiomyopathy [11] and catecholaminergic polymorphic ventricular tachycardia [12]. Thus, using patient-specific iPSCs models for studying ARVC has immense potential benefits, allowing for an increased understanding of the pathogenesis, risk stratification, and diagnosis of ARVC patients, as well as exploration of potential therapeutic options. However, stem cell models must accurately reflect the mutations and characteristics of the disease. In a histopathological study involving myocardial biopsy samples acquired from patients with ARVC, Asimaki et al. found a marked reduction in immunoreactive signals for plakoglobin, but normal levels of the non-desmosomal adhesion molecule N-cadherin in ARVC patients [13]. The authors suggested that this is a potentially useful new diagnostic test with a sensitivity and specificity of 91% and 82%, respectively. The test is limited because it requires myocardial biopsy, an invasive procedure with associated risks. Therefore, a less invasive but accurate and specific test may be more acceptable to patients and have a greater clinical impact. The first in vitro cellular model of ARVC by using patient-specific iPSC-derived cardiomyocytes was described by Ma et al. in 2012. They produced functional iPSC-derived cardiomyocytes by retroviral reprogramming of dermal fibroblasts taken from a male with clinical features of ARVC harboring a PKP2 gene mutation [14]. The results provided novel insights into the disease. First, reduced gene expression of desmosomal proteins (PKP2 and plakoglobin) was observed compared to controls, with lower immunofluorescence signals for these proteins at the cell periphery. Second, after exposure of cardiomyocytes to adipogenic differentiation medium for 2 weeks, the investigators found greater amounts of lipids in ARVC cells compared to in control cells. This was confirmed by both Oil Red O staining for intracellular lipid droplets and qualitatively based on transmission electron microscopy. These findings indicate the abnormal trafficking or expression of desmosomal proteins in mutant cells and indicate an increased adipogenic potential in mutant cells, which may predispose patients to fibro-fatty changes observed in ARVC. Two other groups subsequently published further data on in vitro iPSCs models of ARVC that have improved our understanding of this disease. Kim et al. developed iPSC models using episomal methods from 2 ARVC patients, as well as with PKP2 mutations [15]. Detailed electrophysiological characterization of mutant and control cardiomyocytes and alteration of the external pathogenic conditions using hormones and small molecules resulted in accelerated pathogenesis of the adult-onset phenotype. Important changes in intracellular calcium handling in mutant iPSC-derived cardiomyocytes were also observed, as well as the induction of adult-like metabolism and abnormal peroxisome proliferator-activated receptor gamma (PPAR-γ) activation, which were important in the pathogenesis of ARVC. To explain the predominant pathological characteristics of ARVC in the right ventricle, the investigators increased the number of Islet 1-positive cardiac progenitor cells by approximately 4-fold in mutant PKP2 iPSCs, simulating natural right ventricle formation of the secondary heart field. Caspi et al. also modeled ARVC from 2 patients with PKP2 mutations [16]. Similarly, they found reduced PKP2 and plakoglobin expression as well as increased adipogenicity in ARVC cells, along with upregulation of PPAR-γ. Additionally, they found that the degree of adipogenicity was closely related to the extent of desmosomal abnormalities, suggesting “crosstalk” between desmosomal destruction and adipogenesis, and that ARVC cardiomyocytes were at an increased risk of apoptosis. Despite important advances in our understanding of inherited cardiovascular diseases based on patient-specific iPSC-models, the technology remains challenging and shows some limitations [17]. The currently used models predominantly involve single cells; thus, it is unclear whether these cells replicate more complex processes involving synchronized groups of beating cardiomyocytes at the tissue or organ level, rather than just at the cardiomyocyte level. The currently used models do not fully assess the pathophysiological changes that may affect cell–cell interactions, which may play a role in diseases such as ARVC. Models must be refined to include layers of synchronized functional cardiomyocytes and explore the intercellular interactions in mutant and control cells. Furthermore, ARVC and other cardiomyopathies such as dilated cardiomyopathy are predominantly adult-onset diseases. Because iPSC-derived cardiomyocytes are relatively immature cells, it is unclear whether the changes observed in these cells truly reflect all pathophysiological changes in adult cells. Several novel methods have recently been reported, and they may improve the maturation of iPSC-derived cardiomyocytes and thus help overcome this limitation. These techniques include prolonged in vitro cell culture [18], [19], bio-mimetic culturing using forced expression of Kir2.1 [20], and using a novel platform (consisting of biowires submitted to electrical stimulation) which combines 3-dimensional cell cultivation with electrical stimulation [21]. Finally, although ARVC iPSC-models described to date show adipogenic changes in mutant cells in vitro, the precise mechanisms and external factors responsible for these changes in ARVC patients in vivo remain unknown. Despite these challenges, the ability to use patient-specific iPSCs to model ARVC was shown to be useful in studies of the disease, providing vital knowledge regarding the pathogenesis of AVRC as well as providing opportunities to design and test novel diagnostic strategies and therapeutics. ARVC-iPSC models described to date involved patients with PKP2 gene mutations. Future studies examining ARVC patients with different mutations are necessary to determine whether there is a common pathophysiological abnormality in AVRC or varying mechanisms depending on the specific mutation. More detailed electrophysiological and functional studies are needed to elucidate the mechanisms underlying life-threatening cardiac arrhythmias observed in patients with ARVC. None." @default.
• W2035667023 created "2016-06-24" @default.
• W2035667023 creator A5027095194 @default.
• W2035667023 creator A5027486335 @default.
• W2035667023 date "2014-10-01" @default.
• W2035667023 modified "2023-10-16" @default.
• W2035667023 title "Understanding arrhythmogenic right ventricular cardiomyopathy: Use of patient-specific induced pluripotent stem cell models" @default.
• W2035667023 cites W2022229270 @default.
• W2035667023 cites W2035312069 @default.
• W2035667023 cites W2036211423 @default.
• W2035667023 cites W2058324819 @default.
• W2035667023 cites W2060868333 @default.
• W2035667023 cites W2073795951 @default.
• W2035667023 cites W2079784916 @default.
• W2035667023 cites W2085050235 @default.
• W2035667023 cites W2098466621 @default.
• W2035667023 cites W2104790299 @default.
• W2035667023 cites W2108903695 @default.
• W2035667023 cites W2113047160 @default.
• W2035667023 cites W2115644752 @default.
• W2035667023 cites W2122723517 @default.
• W2035667023 cites W2125987139 @default.
• W2035667023 cites W2131810639 @default.
• W2035667023 cites W2134406150 @default.
• W2035667023 cites W2138203975 @default.
• W2035667023 cites W2165465459 @default.
• W2035667023 cites W2333378562 @default.
• W2035667023 cites W2893639967 @default.
• W2035667023 doi "https://doi.org/10.1016/j.joa.2014.01.001" @default.
• W2035667023 hasPublicationYear "2014" @default.
• W2035667023 type Work @default.
• W2035667023 sameAs 2035667023 @default.
• W2035667023 citedByCount "0" @default.
• W2035667023 crossrefType "journal-article" @default.
• W2035667023 hasAuthorship W2035667023A5027095194 @default.
• W2035667023 hasAuthorship W2035667023A5027486335 @default.
• W2035667023 hasBestOaLocation W20356670231 @default.
• W2035667023 hasConcept C104317684 @default.
• W2035667023 hasConcept C107459253 @default.
• W2035667023 hasConcept C126322002 @default.
• W2035667023 hasConcept C145103041 @default.
• W2035667023 hasConcept C164705383 @default.
• W2035667023 hasConcept C2778198053 @default.
• W2035667023 hasConcept C2778797674 @default.
• W2035667023 hasConcept C54355233 @default.
• W2035667023 hasConcept C71924100 @default.
• W2035667023 hasConcept C86803240 @default.
• W2035667023 hasConceptScore W2035667023C104317684 @default.
• W2035667023 hasConceptScore W2035667023C107459253 @default.
• W2035667023 hasConceptScore W2035667023C126322002 @default.
• W2035667023 hasConceptScore W2035667023C145103041 @default.
• W2035667023 hasConceptScore W2035667023C164705383 @default.
• W2035667023 hasConceptScore W2035667023C2778198053 @default.
• W2035667023 hasConceptScore W2035667023C2778797674 @default.
• W2035667023 hasConceptScore W2035667023C54355233 @default.
• W2035667023 hasConceptScore W2035667023C71924100 @default.
• W2035667023 hasConceptScore W2035667023C86803240 @default.
• W2035667023 hasIssue "5" @default.
• W2035667023 hasLocation W20356670231 @default.
• W2035667023 hasLocation W20356670232 @default.
• W2035667023 hasOpenAccess W2035667023 @default.
• W2035667023 hasPrimaryLocation W20356670231 @default.
• W2035667023 hasRelatedWork W131791058 @default.
• W2035667023 hasRelatedWork W1998556240 @default.
• W2035667023 hasRelatedWork W2044490050 @default.
• W2035667023 hasRelatedWork W2125804349 @default.
• W2035667023 hasRelatedWork W2167036398 @default.
• W2035667023 hasRelatedWork W3035006171 @default.
• W2035667023 hasRelatedWork W3212829433 @default.
• W2035667023 hasRelatedWork W4237806278 @default.
• W2035667023 hasRelatedWork W4247718175 @default.
• W2035667023 hasRelatedWork W1703255818 @default.
• W2035667023 hasVolume "30" @default.
• W2035667023 isParatext "false" @default.
• W2035667023 isRetracted "false" @default.
• W2035667023 magId "2035667023" @default.
• W2035667023 workType "article" @default.